Merck-U02-Substudy 02A_PD-1 Refractory Melanoma - Clinical Trial
What is the Purpose of this Study?
We are doing this study to find out if combining pembrolizumab and different experimental drugs are safe and effective treatments for people with melanoma that does not improve after standard therapy.
PD-1 (Programmed Cell Death Protein 1) Resistant Melanoma
Who Can Participate in the Study?
Adults ages 18+ who:
- Are diagnosed with melanoma
- Did not respond to previous treatment that used anti-PD-1/L1 therapy
For more information about who can be in this study, please contact the study team at email@example.com.
What is Involved?
The study is divided into two periods: a screening period and a study dosing period.
If you choose to join this study, during the screening period you will:
- Have physical exams
- Have blood draws
- Have other tests done to assess your eligibility
The screening period will last for about one month.
If you are found to be eligible, you will continue on to the study dosing period. During this period, you will:
- Be randomly assigned (fair, 50/50 chance) to 1 of 2 groups
-- Group 1 will get pembrolizumab combined with two study drugs called MK-1308 and MK-7684
-- Group 2 will get pembrolizumab combined with lenvatinib and MK-1308